Paclitaxel News and Research RSS Feed - Paclitaxel News and Research

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.
Chemotherapy-induced senescent cells promote side effects and cancer relapse

Chemotherapy-induced senescent cells promote side effects and cancer relapse

Standard chemotherapy is a blunt force instrument against cancer - and it's a rare cancer patient who escapes debilitating side effects from systemic treatments that mostly affect dividing cells, both malignant and healthy, throughout the body. [More]
MGH researchers identify protein that may protect tumor-initiating cells in breast cancer

MGH researchers identify protein that may protect tumor-initiating cells in breast cancer

Massachusetts General Hospital investigators have identified a protein that may play an essential role in maintaining a population of tumor-initiating cells (TICs) -- treatment-resistant cells responsible for cancer recurrence and metastasis -- in breast cancer, as well as a compound that appears to reduce the molecule's ability to protect TICs from the effects of chemotherapy. [More]
Reduced radiation can maintain high cure rates in patients with HPV-related oropharyngeal cancers

Reduced radiation can maintain high cure rates in patients with HPV-related oropharyngeal cancers

Human papillomavirus-positive oropharynx cancers (cancers of the tonsils and back of the throat) are on rise. [More]
Study addresses cost-effectiveness of checkpoint inhibitors for advanced melanoma in Hong Kong

Study addresses cost-effectiveness of checkpoint inhibitors for advanced melanoma in Hong Kong

Immunotherapy with pembrolizumab has been deemed a cost-effective first line treatment for advanced melanoma patients in Hong Kong, researchers report at the ESMO Asia 2016 Congress in Singapore. [More]
ESMO Asia 2016: Three studies present first data on rare sarcomas in Asian patients

ESMO Asia 2016: Three studies present first data on rare sarcomas in Asian patients

The first data on rare sarcomas in Asian patients is presented in three studies today at the ESMO Asia 2016 Congress in Singapore. [More]
Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Finding the ideal combination of targeted, hormonal and chemotherapeutic agents to treat HER2-negative metastatic breast cancer has been challenging researchers for decades. [More]
Virginia Tech and CytImmune Sciences develop more effective and less toxic cancer treatment

Virginia Tech and CytImmune Sciences develop more effective and less toxic cancer treatment

Virginia Tech scientists have developed a new cancer drug that uses gold nanoparticles created by the biotech firm CytImmune Sciences to deliver paclitaxel — a commonly used chemotherapy drug directly to a tumor. [More]
Super-resolution imaging of biological specimens: an interview with Dr. Manasa Gudheti

Super-resolution imaging of biological specimens: an interview with Dr. Manasa Gudheti

Traditional light microscopy techniques such as confocal and wide-field are diffraction-limited in resolution, which is about 200 nm laterally (in xy) and 500 to 600 nm axially (in z). Features that are closer than the diffraction limit will appear blurred in the image. [More]
Drug-eluting stents more beneficial to patients undergoing saphenous vein graft angioplasty

Drug-eluting stents more beneficial to patients undergoing saphenous vein graft angioplasty

Drug-eluting stents had a clear advantage over bare metal stents in patients undergoing revascularisation of saphenous (leg) vein grafts, results of the BASKET-SAVAGE trial show. [More]
New drug delivery system slows and controls tumors not aiming for complete elimination

New drug delivery system slows and controls tumors not aiming for complete elimination

Researchers have created a new drug delivery system that could improve the effectiveness of an emerging concept in cancer treatment - to dramatically slow and control tumors on a long-term, sustained basis, not necessarily aiming for their complete elimination. [More]
Added benefit not proven for orphan drug in treatment of adults with stomach cancer

Added benefit not proven for orphan drug in treatment of adults with stomach cancer

Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. [More]
MDI Biological Laboratory receives NIH grant for research on peripheral neuropathy

MDI Biological Laboratory receives NIH grant for research on peripheral neuropathy

The MDI Biological Laboratory has announced that it has received a grant of $456,500 over two years from the National Institutes of Health for the study of peripheral neuropathy. [More]
Researchers find promising new therapy for both pediatric and adult cancers

Researchers find promising new therapy for both pediatric and adult cancers

A study conducted at Nationwide Children's Hospital has found that a new chemotherapy is effective against both pediatric and adult cancers, and that it allows other chemotherapies to more readily reach their targets. [More]
First-line nivolumab promising in advanced NSCLC

First-line nivolumab promising in advanced NSCLC

Phase I results published in the Journal of Clinical Oncology suggest that nivolumab, either given alone or alongside platinum-based doublet chemotherapy, could have a role in the first-line treatment of advanced non-small-cell lung cancer. [More]
Paclitaxel drug may promote cancer spread at low doses

Paclitaxel drug may promote cancer spread at low doses

New research indicates that paclitaxel, which is the most commonly used chemotherapy for breast cancer, suppresses tumors when given at a certain dosage, but at low doses, it actually promotes cancer spread to the liver. [More]
Rice University researchers synthesize new anti-cancer agent

Rice University researchers synthesize new anti-cancer agent

Rice University scientists have synthesized a novel anti-cancer agent, Thailanstatin A, which was originally isolated from a bacterial species collected in Thailand. [More]
Oncologists to present latest research findings at ASCO annual meeting

Oncologists to present latest research findings at ASCO annual meeting

Oncologists from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will discuss their latest research findings at the American Society for Clinical Oncology annual meeting, June 3-7 in Chicago. [More]
Rice University researchers set stage for large-scale synthesis of cytotoxic agent to treat cancer

Rice University researchers set stage for large-scale synthesis of cytotoxic agent to treat cancer

The lab of Rice University synthetic organic chemist K.C. Nicolaou has reported the streamlined total synthesis of delta12-prostaglandin J3, a molecule previously claimed to kill leukemic cancer cells. [More]
Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

From today, women in Scotland with an advanced and incurable form of cervical cancer could benefit from the targeted treatment Avastin, which has been given the green light by the Scottish Medicines Consortium (SMC) for routine use on the NHS. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Advertisement
Advertisement